11 results
Primary Objectives-To evaluate if mitochondrial dysfunction can be induced in healthy, middle aged subjects, through the use of simvastatin, and whether it can be reversed by oral ubiquinol supplementation. -To validate the techniques NIRS, PpIX-…
The purpose of this study is to evaluate the single dose pharmacokinetics and pivotal bioequivalence of Darunavir (DRV) 800 milligram (mg), Emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 10 mg when administered as a fixed dose…
The purpose of this clinical pilot study is to generate quantitative evidence that the oral administration of 80 mg Simvastatin per day, three weeks before surgery and one week thereafter, will have a significant effect on fibrinolytic activity…
The aim of this study is to assess the safety and tolerability of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis.
Part 1:The purpose of Part 1 of the study is to investigate how much of the OZ439 compound is absorbed into, distributed in, and eliminated from the body (this is called pharmacokinetics) when administered orally as compared to an intravenous (iv;…
are sildenafil, metformin and simvastatin effective in stimulation of ADH independent urine concentration in man?
- To evaluate the single-dose PK and pivotal bioequivalence of 3 compounds darunavir (DRV) 675 mg, FTC 200 mg, and tenofovir alafenamide (TAF) 10 mg in the presence of cobicistat (COBI)150 mg when administered as an fixed-dose combination (FDC) (D/C…
We aim to evaluate *v*3 integrin expression in proven COVID-19 infected patients with respiratory insufficiency and indicative findings on routine contrast-enhanced CT using [68Ga]Ga-DOTA-(RGD)2. If dysfunctional activated endothelium in the lung…
The aim of this study is to investigate the use of cobicistat to reduce the required dose and dose frequency of tofacitinib in the treatment of RA.
The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF.
The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e. AUC) is enhanced when osimertinib is co-administered with cobicistat in patients with relatively low blood concentrations while receiving the standard…